Inogen, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US45780L1044
USD
6.99
0.25 (3.71%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Inogen, Inc. stock-summary
stock-summary
Inogen, Inc.
Pharmaceuticals & Biotechnology
Inogen, Inc. is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company's Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device. Its three portable product offerings, the Inogen One G4, Inogen One G3 and Inogen One G2, at approximately 2.8, 4.8 and 7.0 pounds with a single battery, respectively. Its Inogen One G4, Inogen One G3 and Inogen One G2 are sub-3, sub-5 and sub-10 pound portable oxygen concentrators, respectively. All of its Inogen One systems are equipped with Intelligent Delivery Technology. The Inogen At Home stationary oxygen concentrator allows it to access the non-ambulatory oxygen patient market and serves as a backup to its Inogen One system for ambulatory patients on its rental service.
Company Coordinates stock-summary
Company Details
326 Bollay Dr , GOLETA CA : 93117-5550
stock-summary
Tel: 1 805 56205001 805 8798205
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 44 Schemes (47.9%)

Foreign Institutions

Held by 57 Foreign Institutions (11.41%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Heath Lukatch
Independent Chairman of the Board
Mr. Scott Wilkinson
President, Chief Executive Officer, Director
Mr. Benjamin Anderson-Ray
Independent Director
Mr. Scott Beardsley
Independent Director
Mr. R. Scott Greer
Independent Director
Mr. Raymond Huggenberger
Independent Director
Mr. Loren McFarland
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
92 Million
(Quarterly Results - Jun 2025)
Net Profit:
-4 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 228 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.60

stock-summary
Return on Equity

-12.08%

stock-summary
Price to Book

1.15